Regulation of copper and Iron homeostasis by metal chelators: A possible chemotherapy for alzheimers disease

Accounts of Chemical Research

Volumn 48, Issue 5, 2015, Pages 1332-1339

  Robert, Anne ^a   Liu, Yan ^b   Nguyen, Michel ^a   Meunier, Bernard ^a,b  

^a LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

^b GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; COPPER; IRON; ORGANOMETALLIC COMPOUND;

ALZHEIMER DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HOMEOSTASIS; HUMAN; SYNTHESIS;

ALZHEIMER DISEASE; CHELATING AGENTS; COPPER; HOMEOSTASIS; HUMANS; IRON; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS;

EID: 84929586990     PISSN: 00014842     EISSN: 15204898     Source Type: Journal    
DOI: 10.1021/acs.accounts.5b00119     Document Type: Article

References (79)

1. Thies, W.; Bleiler, L. 2013 Alzheimers disease facts and figures. Alzheimers Association Report Alzheimers Dementia 2013, 9, 208-245
2. http://investor.frx.com/press-release/product-news/fda-approves-namendatm-memantine-hcl-treatment-moderate-severe-alzheimers.
3. Cummings, J. L.; Travis, M.; Zhong, K. Alzheimers disease drug-development pipeline: Few candidates, frequent failure Alzheimers Res. Ther. 2014, 6, 37-43
4. The Lancet Why are drug trials in Alzheimers disease failing? Lancet 2010, 376, 658-658
5. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimers disease: Clinical trials and drug development Lancet Neurol. 2010, 9, 702-716
6. Ayton, S.; Lei, P.; Bush, A. I. Metallostasis in Alzheimers disease Free Radical Biol. Med. 2013, 62, 76-89
7. Tomiyama, T.; Matsuyama, S.; Iso, H.; Umeda, T.; Takuma, H.; Ohnishi, K.; Ishibashi, K.; Teraoka, R.; Sakama, N.; Yamashita, T.; Nishitsuji, K.; Ito, K.; Shimada, H.; Lambert, M. P.; Klein, W. L.; Mori, H. A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo J. Neurosci. 2010, 30, 4845-4856
8. Zussy, C.; Brureau, A.; Keller, E.; Marchal, S.; Blayo, C.; Delair, B.; Ixart, G.; Maurice, T.; Givalois, L. Alzheimers disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-β peptide injection in rats PLoS One 2013, 8 e53117
9. Dong, J.; Atwood, C. S.; Anderson, V. E.; Siedlak, S. L.; Smith, M. A.; Perry, G.; Carey, P. R. Metal binding and oxidation of amyloid-β within isolated senile plaques cores: Raman microscopic evidence Biochemistry 2003, 42, 2768-2773
10. Guilloreau, L.; Combalbert, S.; Sournia-Saquet, A.; Mazarguil, H.; Faller, P. Redox chemistry of copper-amyloid-β: The generation of hydroxyl radical in the presence of ascorbate is linked to redox-potentials and aggregation state ChemBioChem 2007, 8, 1317-1325
11. Jiang, D.; Men, L.; Wang, J.; Zhang, Y.; Chickenyen, S.; Wang, Y.; Zhou, F. Redox reaction of copper complexes formed with different β-amyloid peptides and their neuropathological relevance Biochemistry 2007, 46, 9270-9282
12. Schlief, M. L.; Craig, A. M.; Gitlin, J. D. NMDA receptor activation mediates copper homeostasis in hippocampal neurons J. Neurosci. 2005, 25, 239-246
13. Bayer, T. A.; Schäfer, S.; Simons, A.; Kemmling, A.; Kamer, T.; Tepest, R.; Eckert, A.; Schüssel, K.; Eikenberg, O.; Sturchler-Pierrat, C.; Abramowski, D.; Staufenbiel, M.; Multhaup, G. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces Aβ production in APP23 transgenic mice Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 14187-14192
14. Crichton, R. R.; Dexter, D. T.; Ward, R. J. Brain iron metabolism and its perturbation in neurological diseases J. Neural Transm. 2011, 118, 301-314
15. Bousejra-ElGarah, F.; Bijani, C.; Coppel, Y.; Faller, P.; Hureau, C. Iron(II) binding to amyloid-β, the Alzheimers peptide Inorg. Chem. 2011, 50, 9024-9030
16. Aliès, B.; Sasaki, I.; Proux, O.; Sayen, S.; Guillon, E.; Faller, P.; Hureau, C. Zn impact Cu coordination to amyloid-β, the Alzheimers peptide, but not the ROS production and the associated cell toxicity Chem. Commun. 2013, 49, 1214-1216
17. Crouch, P. J.; Tew, D. J.; Du, T.; Nguyen, D. N.; Caragounis, A.; Filiz, G.; Blake, R. E.; Trounce, I. A.; Soon, C. P. W.; Laughton, K.; Perez, K. A.; Li, Q.-X.; Cherny, R. A.; Masters, C. L.; Barnham, K. J.; White, A. R. Restored degradation of the Alzheimers amyloid-β peptide by targeting amyloid formation J. Neurochem. 2009, 108, 1198-1207
18. Duce, J. A.; Tsatsanis, A.; Cater, M. A.; James, S. A.; Robb, E.; Wikhe, K.; Leong, S. L.; Perez, K.; Johanssen, T.; Greenough, M. A.; Cho, H. H.; Galatis, D.; Moir, R. D.; Masters, C. L.; McLean, C.; Tanzi, R. E.; Cappai, R.; Barnham, K. J.; Ciccotosto, G. D.; Rogers, J. T.; Bush, A. I. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimers disease Cell 2010, 142, 857-867
19. Xiong, Y.; Jing, X.-P.; Zhou, X.-W.; Wang, X.-L.; Yang, Y.; Sun, X. Y.; Qiu, M.; Cao, F. Y.; Lu, Y.-M.; Liu, R.; Wang, J.-Z. Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation Neurobiol. Aging 2013, 34, 745-756
20. Barnham, K. J.; Bush, A. I. Biological metals and metal-targeting compounds in major neurodegenerative diseases Chem. Soc. Rev. 2014, 43, 6727-6749
21. Telpoukhovskaia, M. A.; Orvig, C. Werner coordination chemistry and neurodegeneration Chem. Soc. Rev. 2013, 42, 1836-1846
22. Faller, P.; Hureau, C. A bioinorganic view of Alzheimers disease: When misplaced metal ions (re)direct the electrons to the wrong target Chem.-Eur. J. 2012, 18, 15910-15920
23. Perez, L. R.; Franz, K. J. Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease Dalton Trans. 2010, 39, 2177-2187
24. Ward, R. J.; Zucca, F. A.; Duyn, J. H.; Crichton, R. R.; Zecca, L. The role of iron in brain ageing and neurodegenerative disorders Lancet Neurol. 2014, 13, 1045-1060
25. Cordonnier, C.; Van der Flier, W. M. Brain microbleeds and Alzheimers disease: Innocent observation or key player? Brain 2011, 134, 335-344
26. Barone, E.; Di Domenico, F.; Mancuso, C.; Butterfield, D. A. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: Its time for reconciliation Neurobiol. Dis. 2014, 62, 144-159
27. Guo, C.; Wang, T.; Zheng, W.; Shan, Z.-Y.; Teng, W.-P.; Wang, Z.-Y. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimers disease Neurobiol. Aging 2013, 34, 562-575
28. Liu, Z. D.; Kayyali, R.; Hidder, R. C.; Porter, J. B.; Theobald, A. E. Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: Structure-activity investigation of metalloenzyme inhibition by iron chelators J. Med. Chem. 2002, 45, 631-639 and references therein.
29. Sheppard, L. N.; Kontoghiorghes, G. J. Comparative iron binding studies of bis- and tris(3-hydroxy-2methylpyridin-4-ones) and deferrioxamine Inorg. Chim. Acta 1991, 188, 177-183
30. Scott, L. E.; Page, B. D. G.; Patrick, B. O.; Orvig, C. Altering pyridone N -substituents to optimize activity as potential prodrugs for Alzheimers disease Dalton Trans. 2008, 6364-6367
31. Green, D. E.; Bowen, M. L.; Scott; Storr, T.; Merkel, M.; Böhlmerle, K.; Thompson, K. E.; Patrick, B. O.; Schugar, H. J.; Orvig, C. In vitro studies of 3-hydroxy-4-pyridinones and their glycosylated derivatives as potential agents for Alzheimers disease Dalton Trans. 2010, 39, 1604-1615
32. El-Jammal, A.; Howell, P. L.; Turner, M. A.; Li, N.; Templeton, D. M. Copper complexation by 3-hydroxypyridin-4-one iron chelators: Structural and iron competition studies J. Med. Chem. 1994, 37, 461-466
33. Zhou, T.; Hider, R. C.; Liu, Z. D.; Neubert, H. Iron(III)-selective dendritic chelators Tetrahedron Lett. 2004, 45, 9393-9396
34. Liu, G.; Men, P.; Harris, P. L. R.; Rolson, R. K.; Perry, G.; Smith, M. A. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance Neurosci. Lett. 2006, 406, 189-193
35. Kamalinia, G.; Khodagholi, F.; Atyabi, F.; Amini, M.; Shaerzadeh, F.; Sharifzadeh, M.; Dinarvand, R. Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: In vitro and in vivo studies Mol. Pharmaceutics 2013, 10, 4418-4431
36. Malm, T. M.; Iivonen, H.; Goldsteins, G.; Keksa-Goldsteine, V.; Ahtoniemi, T.; Kanninen, K.; Salminen, A.; Auriola, S.; VanGroen, T.; Tanila, H.; Koistinaho, J. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting β-amyloid burden J. Neurosci. 2007, 27, 3712-3721
37. Choi, J.-S.; Braymer, J. J.; Nanga, R. P. R.; Ramamoorthy, A.; Lim, M. H. Design of small molecules that target metal-Aβ species and regulate metal induced Aβ-aggregation and neurotoxicity Proc. Natl. Acad. Sci. U.S.A. 2011, 107, 21990-21995
38. Beck, M. W.; Oh, S. B.; Kerr, R. A.; Lee, H. J.; Kim, S. H.; Kim, S.; Jang, M.; Ruotolo, B. T.; Lee, J.-Y.; Lim, M. H. A rationally designed small molecule for identifying an in vivo link between metal-amyloid-β complexes and the pathogenesis of Alzheimers disease Chem. Sci. 2015, 6, 1879-1886
39. Lakatos, A.; Zsigó, é.; Hollender, D.; Nagy, N. V.; Fülöp, L.; Simon, D.; Bozsó, L.; Kiss, T. Two pyridine derivatives as potential Cu(II) and Zn(II) chelators in therapy for Alzheimers disease Dalton Trans. 2010, 39, 1302-1315
40. Storr, T.; Merkel, M.; Song-Zhao, G. X.; Scott, L. E.; Green, D. E.; Bowen, M. L.; Thompson, K. H.; Patrick, B. O.; Schugar, H. J.; Orvig, C. Synthesis, characterization, and metal coordination ability of multifunctional carbohydrate-containing compounds for Alzheimers therapy J. Am. Chem. Soc. 2007, 129, 7453-7463
41. Noël, S.; Perez, F.; Pedersen, J. T.; Aliès, B.; Ladeira, S.; Sayen, S.; Guillon, E.; Gras, E.; Hureau, C. A new water-soluble Cu(II) chelator that retrieves Cu from Cu(amyloid-β) species, stops associated ROS production and prevents Cu(II)-induced Aβ aggregation J. Inorg. Biochem. 2012, 117, 322-325
42. Noël, S.; Bustos Rodriguez, S.; Sayen, S.; Guillon, E.; Faller, P.; Hureau, C. Use of a new water-soluble Zn sensor to determine Zn affinity for the amyloid-β peptide and relevant mutants Metallomics 2014, 6, 1220-1222
43. Singh, S. K.; Sinha, P.; Mishra, L.; Srikrishna, S. Neuroprotective role of a novel copper chelator against Aβ42 induced neurotoxicity Int. J. Alzheimers Dis. 2013, 567128
44. Donnelly, P. S.; Caragounis, A.; Du, T.; Laughton, K. M.; Volitakis, I.; Cherny, R. A.; Sharples, R. A.; Hill, A. F.; Li, Q.-X.; Masters, C. L.; Barnham, K. J.; White, A. R. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-β peptide J. Biol. Chem. 2008, 283, 4568-4577
45. Folk, D. S.; Franz, K. J. A prochelator activated by β-secretase inhibits Aβ aggregation and suppresses copper-induced reactive oxygen species formation J. Am. Chem. Soc. 2010, 132, 4994-4995
46. Amijee, H.; Bate, C.; Williams, A.; Virdee, J.; Jeggo, R.; Spanswick, D.; Scopes, D. I. C.; Treherne, J. M.; Mazzitelli, S.; Chawner, R.; Eyers, C. E.; Doig, A. J. The N-methylated peptide SEN304 powerfully inhibits Aβ(1-42) toxicity by perturbing oligomer formation Biochemistry 2012, 51, 8338-8352 and references therein.
47. Geng, J.; Li, M.; Wu, L.; Ren, J.; Qu, X. Liberation of copper from amyloid plaques: Making a risk factor useful for Alzheimers disease treatment J. Med. Chem. 2012, 55, 9146-9155
48. Huang, L.; Lu, C.; Sun, Y.; Mao, F.; Luo, Z.; Su, T.; Jiang, H.; Shan, W.; Li, X. Multitarget-directed benzylideneindanone derivatives: Anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO B) inhibition properties against Alzheimers disease J. Med. Chem. 2012, 55, 8483-8492
49. Youdim, B. H. M. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs Ladostigil and M30 derived from Rasigiline Exp. Neurobiol. 2013, 22, 1-10
50. Zheng, H.; Youdim, M. B. H.; Fridkin, M. Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities ACS Chem. Neurosci. 2010, 1, 737-746
51. Li, S.-Y.; Jiang, N.; Xie, S.-S.; Wang, K. D. G.; Wang, X.-B.; Kong, L.-Y. Design, synthesis and evaluation of novel tacrine-rhein hybrids as functional agents for the treatment of Alzheimers disease Org. Biomol. Chem. 2014, 12, 801-814p
52. Huang, W.; Lv, D.; Yu, H.; Shen, R.; Kim, S. C.; Wu, P.; Luo, K.; Li, J.; Hu, Y. Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimers disease Bioorg. Med. Chem. 2010, 18, 5610-5615
53. Wang, Z.; Wang, Y.; Li, W.; Mao, F.; Sun, Y.; Huang, L.; Li, X. Design, synthesis, and evaluation of multitarget directed selenium-containing clioquinol derivatives for the treatment of Alzheimers disease ACS Chem. Neurosci. 2014, 5, 952-962
54. Chaudiere, J.; Wilhelmsen, E. C.; Tappel, A. L. Mechanism of selenium-glutathione peroxidase and its inhibition by mercaptocarboxylic acids and other mercaptans J. Biol. Chem. 1984, 259, 1043-1050
55. Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean, C. A.; Barnham, K. J.; Volitakis, I.; Fraser, F. W.; Kim, Y.-S.; Huang, X.; Goldstein, L. E.; Moir, R. D.; Lim, J. T.; Beyreuther, K.; Zheng, H.; Tanzi, R. E.; Masters, C. L.; Bush, A. I. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimers disease transgenic mice Neuron 2001, 30, 665-676
56. Takeda, A.; Takada, S.; Ando, M.; Itagaki, K.; Tamano, H.; Suzuki, M.; Iwaki, H.; Oku, N. Impairment of recognition memory and hippocampal long term potentiation after acute exposure to chloroquinol Neuroscience 2010, 171, 443-450
57. http://www.drugbank.ca/drugs/db04815.
58. Arbiser, J. L.; Kraeft, S.-K.; van Leeuwen, R.; Hurwitz, S. J.; Selig, M.; Dickersin, G. R.; Flint, A.; Byers, H. R.; Chen, L. B. Clioquinol-zinc chelate: A candidate causative agent of subacute myelo-optic neuropathy Mol. Med. 1998, 4, 665-670
59. Andersson, D. A.; Gentry, C.; Moss, S.; Bevan, S. Clioquinol and pyrithione activate TRPA1 by increasing intracellular Zn2+ Proc. Natl. Acad. Sci. U.S.A. 2009, 109, 8374-8379
60. Phillips, J. P. The reactions of 8-quinolinol Chem. Rev. 1956, 56, 271-297
61. Ferrada, E.; Arancibia, V.; Loeb, B.; Norambuena, E.; Olea-Azar, C.; Huidobro-Toro, J. P. Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimers and Huntingtons disease therapy Neurotoxicology 2007, 28, 445-449
62. Faux, N. G.; Ritchie, C. W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C. L.; Tanzi, R. E.; Cummings, J. L.; Herd, C. M.; Bush, A. I. PBT2 rapidly improves cognition in Alzheimers disease: additional phase II analyses J. Alzheimers Dis. 2010, 20, 509-516
63. http://www.prnewswire.com/news-releases/prana-biotechnology-announces-preliminary-results-of-phase-2-imagine-trial-of-pbt2-in-alzheimers-disease-253173581.html.
64. Huntington Study Group Reach2HD Investigators Safety, tolerability, and efficacy of PBT2 in Huntingtons disease: A phase 2, randomised, double-blind, placebo-controlled trial Lancet Neurol. 2015, 14, 39-47
65. Li, M.; Shi, P.; Xu, C.; Ren, J.; Qu, X. Cerium oxide caged metal chelator: Anti-aggregation and anti-oxidation integrated H2O2-responsive controlled drug release for potential Alzheimers disease treatment Chem. Sci. 2013, 4, 2536-2542
66. Park, E.-J.; Choi, J.; Park, Y.-K.; Park, K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells Toxicology 2008, 245, 90-100
67. Shi, P.; Li, M.; Ren, J.; Qu, X. Gold nanocage-based dual responsive "caged metal chelator" release system: Noninvasive remote control with near infrared for potential treatment of Alzheimers disease Adv. Funct. Mater. 2013, 23, 5412-5419
68. Oliveri, V.; Attanasio, F.; Puglisi, A.; Spencer, J.; Sgarlata, C.; Vecchio, G. Multifunctional 8-hydroxyquinoline-appended cyclodextrins as new inhibitors of metal-induced protein aggregation Chem.-Eur. J. 2014, 20, 8954-8964
69. Di Vaira, M.; Bazzicalupi, C.; Orioli, P.; Messori, L.; Bruni, B.; Zatta, P. Clioquinol, a drug for Alzheimers disease specifically interfering with brain metal metabolism: Structural characterization of its zinc(II) and copper(II) complexes Inorg. Chem. 2004, 43, 3795-3797
70. Matlack, K. E. S.; Tardiff, D. F.; Narayan, P.; Hamamichi, S.; Caldwell, K. A.; Caldwell, G. A.; Lindquist, S. Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 4013-4018
71. Treiber, C.; Simons, A.; Strauss, M.; Hafner, M.; Cappai, R.; Bayer, T. A.; Multhaup, G. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimers disease J. Biol. Chem. 2004, 50, 51958-51964
72. Adlard, P. A.; Cherny, R. A.; Finkelstein, D. I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J. P.; Perez, K.; Laughton, K.; Li, Q. X.; Charman, S. A.; Nicolazzo, J. A.; Wilkins, S.; Delava, K.; Lynch, T.; Kok, G.; Richtie, C. W.; Tanzi, R. E.; Cappai, R.; Masters, C. L.; Barnham, K. J.; Bush, A. I. Rapid restoration of cognition in Alzheimers transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta Neuron 2008, 59, 43-55
73. Nguyen, M.; Rechignat, L.; Robert, A.; Meunier, B. The necessity of having a tetradentate ligand to extract copper(II) ion from amyloid ChemistryOpen 2015, 4, 27-31
74. Kenche, V. B.; Zawisza, I.; Masters, C. L.; Bal, W.; Barnham, K. J.; Drew, S. C. Mixed ligands Cu2+ complexes of a model therapeutic with Alzheimers amyloid-β peptide and monoamine neurotransmitters Inorg. Chem. 2012, 52, 4303-4318
75. Deraeve, C.; Boldron, C.; Maraval, A.; Mazarguil, H.; Gornitzka, H.; Vendier, L.; Pitié, M.; Meunier, B. Preparation and study of new poly-8-hydroxyquinoline chelators for an anti-Alzheimer strategy Chem.-Eur. J. 2008, 14, 682-696
76. Deraeve, C.; Pitié, M.; Mazarguil, H.; Meunier, B. Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents New J. Chem. 2007, 31, 193-195
77. Deraeve, C.; Maraval, A.; Vendier, L.; Faugeroux, V.; Pitié, M.; Meunier, B. Preparation of new bis(8-aminoquinoline) ligands and comparison with bis(8-hydroxyquinoline) ligands on their ability to chelate CuII and ZnII Eur. J. Inorg. Chem. 2008, 5622-5631
78. Nguyen, M.; Robert, A.; Sournia-Saquet, A.; Vendier, L.; Meunier, B. Characterization of new specific copper chelators as potential drugs for Alzheimers disease treatment Chem.-Eur. J. 2014, 20, 6771-6785
79. Ceccom, J.; Coslédan, F.; Halley, H.; Francès, B.; Lassalle, J.-M.; Meunier, B. Copper chelator induced efficient episodic memory recovery in a non-transgenic alzheimers mouse model PLosOne 2012, 7 e43105